Geron Stock (NASDAQ:GERN)
Previous Close
$1.72
52W Range
$1.46 - $5.34
50D Avg
$2.79
200D Avg
$3.92
Market Cap
$1.10B
Avg Vol (3M)
$14.88M
Beta
0.53
Div Yield
-
GERN Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TGTX | TG Therapeutics, Inc. |
| PDSB | PDS Biotechnology Corporation |
| ZURA | Zura Bio Limited |
| SRPT | Sarepta Therapeutics, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| PTCT | PTC Therapeutics, Inc. |
| CWBR | CohBar, Inc. |
| AVRO | AVROBIO, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |